Case ReportOpen Access

CHOP-treated Mammary Non-hodgkin's Malignant Lymphoma in a Female Patient with HIV + On Retroviral Treatment - Case Report

ยทยทยทยท
DOI: 10.23958/ijirms/vol04-i05/633ยท Pages: 309 to 311ยท Vol. 4, No. 05, (2019)ยท Published: May 10, 2019
PDF
Views: 418 PDF downloads: 159

Abstract

HIV infection greatly increases the risk of developing lymphoma. NHL is present in approximately 3% of the HIV-positive population at the time of their HIV diagnosis. Twenty percent of HIV-positive patients develop NHL. Risk factors for an association of the NHL with HIV include: low CD4 T cell count, high viral load, age, and male.

We report the case of a 35-year-old mother of three children having a history of the death of the husband following the neurological complications of AIDS, the patient was subsequently diagnosed with HIV + and then placed on retroviral treatment. After 6 months the patient reported a breast swelling with pelvic pain, a breast biopsy performed showing a large B-cell NHL.

The extension assessment reveals localizations: mammary, bilateral ovarian and adrenal right of a lymphomatous process, the BOM is normal and the CD4 rate is 517 / mm3. CHOP-type systemic chemotherapy with intrathecal chemotherapy has been initiated. The post-treatment evaluation was in favor of a complete clinical and radiological response.

The prognosis of patients with AIDS-related lymphoma is associated with the stage of the disease, extraganglionic involvement including bone marrow, CD4 cell count, and performance status. Median survival varies from 8 to 20 months, which remains much lower than that of non-HIV-associated lymphomas.

Keywords

large B-cell NHLbreastCHOPHIV+
Author details
K. El Bakraoui
Department of Medical Oncology, National Institute of Oncology, CHU Rabat, Morocco
โœ‰ Corresponding Author
๐Ÿ‘ค View Profile โ†’
I. El Ghissassi
Department of Medical Oncology, National Institute of Oncology, CHU Rabat
๐Ÿ‘ค View Profile โ†’
S. Boutayeb
Department of Medical Oncology, National Institute of Oncology, CHU Rabat
๐Ÿ‘ค View Profile โ†’
H. Mrabet
Department of Medical Oncology, National Institute of Oncology, CHU Rabat, Morocco
๐Ÿ‘ค View Profile โ†’
H. Errihani
Department of Medical Oncology, National Institute of Oncology, CHU Rabat, Morocco
๐Ÿ‘ค View Profile โ†’